South Korea FDA Accused Of Lax Monitoring Of Sibutramine Drugs
This article was originally published in PharmAsia News
Executive SummarySouth Korea's FDA is being criticized for being lax in its regulation of the weight-loss drug sibutramine, now banned in the United States, Europe and other markets
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.